Inhibitor Therapeutics (INTI) CEO Francis O'Donnell Receives Award

What Happened Francis E. O'Donnell Jr., CEO of Inhibitor Therapeutics (INTI), was granted 50,000 shares of restricted common stock on May 4, 2026. The shares were issued as an award (transaction code A) at a $0.00 price (total reported consideration $0). The grant is compensation under the company's 2025 Equity Incentive Plan and is subject to shareholder approval per the filing footnote.

Key Details

• Transaction date: 2026-05-04 — Award of 50,000 shares @ $0.00 (code A).
• Consideration: $0.00 reported (compensation award).
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: Represents restricted common stock issued as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval (F1).
• Filing timeliness: Report filed 2026-08-04 for a 2026-05-04 transaction (late filing). Form 4s are typically due within two business days of the transaction; late filings reduce near-term transparency.

Context This was a compensation award of restricted stock, not an open-market purchase or sale. Restricted shares typically vest over time and may be forfeitable if vesting conditions or shareholder approval are not met, so the grant does not necessarily indicate immediate buying or selling intent. Awards to executives are common as part of incentive compensation packages.